Introduction
Microbial vectors have been developed for several reasons: to ensure efficient delivery to somatic cells, to increase the antigen produced, and to increase their potency by the provision of adjuvant or the activation of innate immune responses. Viruses have evolved highly efficient structures and mechanisms for infecting cells and utilizing the cellular machinery for production of virally encoded proteins. Thus, viral vectors are natural preferred vehicles for heterologous gene delivery for immune responses and have been extensively studied and developed as such [1] .
Most viral vectors are developed using viruses that are associated with mild or no disease or using viruses that are pathogenic but attenuated by deletion of virulence genes. Replication competent virus vectors, which can produce progeny virus, as well as replicationdefective virus vectors, which do not produce progeny virus, have been developed and evaluated as vaccine delivery vehicles [2] .
A number of viral vectors have been developed or are in the process of being developed, improved and evaluated. These include DNA viruses such as Adenoviruses, Herpes viruses and Pox viruses that have been used in a wide range of applications [3, 4] where as replication deficient human Adenovirus vectors have been used very successfully in the development of foot and mouth disease virus vaccines [5] . The major advantage of live vectors is that they produce the antigen in its native conformation, which is important for generating neutralizing antibodies and can facilitate antigen entry into the MHC class I processing pathway for the induction of CD8+CT [6] .
Adeno viruses have shown tremendous promise as delivery vehicles for recombinant vaccination and gene therapy. Adeno virus vectors are suitable candidates for gene delivery applications. Adenoviruses are ubiquitous pathogens associated with mild or no diseases in immune competent animals such as birds, mammals, reptiles and amphibians. The ability to infect a wide range of actively dividing and non dividing mammalian cells and to induce a high level of transgene expression made Adenovirus to develop high levels of antigen specific humoral and cell mediated immune responses in response to vector delivery either via a systemic or mucosal route. The adenoviral genome is well characterized, comparatively easy to manipulate and minimum risk of integration into the host genome. They can be applied systemically as well as through mucosal surfaces and their relative thermo stability facilitates their clinical use [7] .
Therefore, the objectives of this seminar paper are:
 To outline the basic principles of adenovirus vector construction.  To provide insight on the application and challenges of adenovirus as a vaccine vector.
Adeno Virus Structure and Replication Virion Property
Adenoviruses were first isolated from cultures of human adenoid tissue (tissue located at the back of the nose, above the tonsils) and were discovered in 1953. Adenoviruses are medium sized (90-100 nm), non enveloped, icosahedrally symmetric double stranded DNA viruses. The genome of adenovirus is approximately 34 -43kb and to conserve space, it encodes polypeptides from both DNA strands and uses alternative splicing and different polyadenylation sites [8] .
The adenovirus capsid is composed primarily of 240 homotrimeric hexon capsomers with twelve Penton capsomers located at each of the twelve fivefold axes of symmetry. The capsid of the virus contains three major proteins: Hexon, Fibre and Penton Base proteins. The Hexon protein provides structural support, but differs in size and immunological properties between serotypes. The fiber protein of adenovirus exhibit high homology among serotypes and occurs as a trimer on the surface of the capsid. The fibre proteins are anchored to the capsid by the penton base proteins, which occur as a pentamer. Together with the fiber protein, it is responsible for the attachment of the virus to cell surfaces [9] .
The capsid is stabilized by several minor scaffolding proteins: VI, VIII, IX, IIIa, and IVa2. Protein VI is located beneath the hexons in the viral capsid. When the virus enters the host cells, the lowered pH causes destabilization of the capsid, which liberates protein VI and promotes membrane disruption [10] . Proteins VIII and IX are thought to aid in stabilization and/or assembly of the virion. Protein IIIa is associated with the penton base and is critical to major late mRNA and protein expression [11] . Protein IVa2 plays a role in viral DNA packaging and is a transcriptional activator of the major late promoter. Research suggests that the IVa2 protein plays a role in viral DNA packaging and that a functional interaction between IVa2 and the rest of adenovirus packaging machinery is serotype specific [12] .
Its genome carries five early genes: E1A, E1B, E2, E3, and E4 [14] . The E1A gene induces expression of other viral early genes. The E1B gene delays host cell lysis during viral replication and after replication is complete, it induces apoptosis and controls the export of viral transcripts. Deletion of E1 results in viruses that are severely impaired in their ability to replicate and allows for the insertion of approximately 5.1kb of new DNA [15] .
Virus Replication
Adenoviruses replicate in the nucleus, and their replication is facilitated by extensive modulation of the host immune response. Viruses bind to host cell receptors via their Penton fiber knobs and subsequent internalization is mediated by the interaction between the Penton base and cellular integrins. The outer capsid is then removed and the core comprising the viral genome with its associated histones enters the nucleus where messenger RNA (mRNA) transcription, viral DNA replication, and assembly of virions occur. In the nucleus, the genome is transcribed by cellular RNA polymerase II according to a complex program involving both DNA strands [17] .
Replication is divided into two phases: early and late. 
Deletion:
The adenoviral capsid allows some latitude regarding the length of genome that can be packaged efficiently. Foreign sequences of up to 1.8 kb can be inserted into the adenoviral genome without necessitating deletions. Nevertheless, to increase the permitted size of the insert and to modify the biology of adenoviral vectors, vaccine constructs are generally based on Adenoviral vectors with deletions of transcription units. The initial adenoviral vaccine vectors were deleted of E3, which encodes gene products that are nonessential for virus replication [23] .
Most vectors currently used as vaccine carriers are deleted in E1 gene. This not only renders the vectors replication defective but also allows for sustained antigen presentation by reducing the vectors' ability to induce death of the infected cells. E1 is essential for viral replication and therefore has to be provided in Trans during production of the vectors. To incorporate larger foreign sequences, vectors deleted of E1 and E3 have been develop and they accommodate up to 7.5 kb of foreign DNA [24] .
The original E1 deleted Adenoviral vectors were constructed by homologous recombination. Cells were co-transfected with purified Adenoviral genome deleted of E1 by restriction enzyme digest and a shuttle vector that contained the left handed ITR, the E1a enhancer, the encapsidation signal, the cytomegalovirus (CMV) IE promoter (or another suitable promoter), a multi cloning site for insertion of the gene of interest, and the SV40 poly (A) signal followed by sequences from the Adenoviral genome located 3' of the E1 domain. Now most E1-deleted Adenoviral vectors are generated from so-called molecular clones in which the entire Adenoviral genome including the ITRs is carried in a bacterial plasmid, allowing for its propagation in Escherichia coli [25] E3 deleted Adenoviral vectors are replication competent and thus less predictable than replication defective vectors. This raises concern about potential toxicity especially if they are used in immune compromised patients. It has been argued that replication competent denoviruses achieve higher antigenic loads compared to replication defective vectors and thus result in higher and more sustained transgene product-specific immune responses [26] .
Replication competent adenoviral vectors: Replication competent adenoviral vectors encode all of the remaining adenoviral antigens in addition to the transgene product, i.e., The vaccine antigen. The adaptive immune response will thus be directed toward a multitude of different antigens, which can negatively affect the desired immune response to the vaccine antigen through competition for MHC binding sites or cytokines needed for activation, differentiation and proliferation of T and B cells. Furthermore, adenoviruses cause in most cell types lytic infections and, once the viral progeny has been assembled, result in apoptotic death of the infected cells. This shortens the duration of antigen presentation by individual infected cells, which in turn could have a negative effect on induction of CD8 + T cells, which are stimulated primarily by peptides derived from denovo synthesized antigens, while potentially favoring activation of CD4 + T cells, which are induced by peptides derived from lysosomal cleavage of proteins taken up by phagocytosis or pinocytosis [24] .
Replication incompetent adenoviral vectors:
Replication incompetent vectors contain an antigen expression cassette substituted for the deleted E1A-E1B region. These replication incompitant adenoviruses can not replicate because of the deletion of the essential viral E1 gene region containing two genes, E1a and E1b. The removal of the E1 gene region creates room for the vaccine expression cassette and prohibits transactivation of viral genes required for viral replication. In addition to the E1 deletion, the viral E3 gene is dispensable for production of recombinant virus as well as the E4 gene, which reduces proinflammatory responses in vivo. Typically, the E3 region is also deleted to accommodate larger insertions. Regions of E2 and/or E4 can be deleted to diminish expression of late viral genes. Helper dependant vectors are deleted of all viral genetic information except the termini and the packaging sequence, which are required for vector propagation by helper systems. The antigen expression cassette is inserted into the deleted region together with a 'filler' sequence, so that the overall vector length is approximately the 36 kbp size similar to native Ad, to achieve efficient propagation [27] . Replication selective adenoviruses contain deletions in E1A or E1B, which render their propagation selective in cancer cells deficient in p53 or pRB function. Alternatively, tissue specific promoters can be substituted for the E1A promoter, so that productive virus infection occurs selectively in tumors having appropriate factors for activity of these promoters [28] . In another report, the fiber of the subtype C AdHu5 virus was replaced with that of a subtype B fiber, i.e., the one derived from AdHu35 virus. Again, the pseudo typed vector has an increased ability to transduce dendritic cells and results in improved induction of CD8 + T cells in vitro or in vivo upon transfer of transduced dendritic cells [34] .
Immune Responses Generated by Adenoviral Vectors
Both innate and adaptive immune responses are induced by adenoviral vectors and responses are generated against the transgene but also the vector itself. Following systemic administration, adenoviral vectors will attach to the Coxsackie Adenovirus Receptor (CAR) on host cells and are internalized. Initially entering the cell within an endosome the virus subsequently escapes from the endosome and from within the cytoplasm the viral DNA will enter the nucleus of the cell and is eventually transcribed [35] . 
Adenoviral Vectors Currently Used in Veterinary Vaccines
The appeal of adenovirus based vaccine vectors stems from their use as efficacious vaccines. Most studies to date have focused on human serotype adenoviruses, particularly human adenovirus type 5. Human serotype adenovirus vaccine vectors are particularly useful for development of veterinary vaccines as neutralizing antibodies to the vector will not usually be present in the vaccinates and to date a range of veterinary vaccine candidates have been developed using this platform [43] . Adeno viruses from various species have been developed as vectors and some examples are listed in Table 1 .
Vector
Animal Model Currently however, veterinary vaccines comprise a fraction of the market size of human vaccines; consequently there are much lower levels of investment into veterinary vaccine research and development. These issues can have a negative impact on the utilization of new technologies in veterinary vaccine development. The commercialization of vaccines whether for human or veterinary use usually begins following extensive testing of the vaccine candidate in animal models and field trials? The final stage of this arduous process would be market authorization which for a veterinary vaccine would involve obtaining permission from veterinary authorities to allow the vaccine to be made available to the relevant consumers [51] .
Route of delivery

Results of animal studies Reference
Over the years a number of adenoviral vector based veterinary vaccines have been developed but none are currently licensed. One such Adenoviral vector based veterinary vaccine is currently under consideration for commercialization. This is a replication defective human adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot and mouth disease virus as a vaccine candidate has been developed and gone through field trials and other testing in preparation for commercial production [52] .
Challenges in Application of Adenoviral Vaccine Vector
Despite the many advantages of this technology there are some potential drawbacks to consider, such as the potential toxicity of adenoviral vaccine vectors. For example, viral based vectors elicit an inflammatory cytokine response (by stimulating both innate and adaptive immune responses), thus promoting harmful side effects in the host. In light of this, these viral vaccine vectors must be thoroughly evaluated for potentially harmful immunological reactions on the host immune system, especially in the context of pre-existing immunity to the vaccine vector prior to conducting field trials [53] .
Adenoviral vector based systems are clearly underutilized in veterinary vaccine development despite being well characterized and shown to be potent inducers of protective immune responses. If these vectors are to be used widely to construct veterinary vaccines that can be commercialized, more research needs to be undertaken on this platform, particularly studies focusing on the comparison of this platform with other viral vector platforms and the use of adenoviral vaccines in prime boost immunization protocols with non Adenoviral vector based vaccines [54] .
Other important issues to be considered when developing Adenoviral vector based on vaccines are the choice of transgene and the stability of the vector genome. Ideally extensive research to identify the most immunogenic antigens of a pathogen should therefore be undertaken before vaccine development begins. In order for a vaccine to be protective, the pathogen specific transgene used in the construction of the vaccine should contain highly immunogenic epitopes otherwise the immune responses generated by the vaccine will be suboptimal. Studies conducted to ensure the stability of the viral vector genome must also be conducted soon after the vaccine is constructed and well before large scale production of the vaccine as it has been reported that mutants which do not express the vaccine transgene can randomly arise when producing large quantities of viral vector based vaccines [55] .
Due to the ubiquitous nature of Adenovirus, a large percentage of animal population has variable levels of neutralizing antibodies know as 'preexisting vector immunity' or 'vector immunity' against more than one Adenovirus serotypes. These neutralizing antibodies are directed against the viral capsid components and adversely affect the uptake of Adenoviral vectors by target cells. Adenovirus neutralizing antibodies persist for years posing a challenge when repeated administrations are necessary [56] .
Preexisting immunity due to natural infections results in sustained virus neutralizing antibody titers, a major handicap for the successful use of common serotypes of Adenovirus, as carriers for gene replacement therapy or vaccine carriers. Neutralizing antibodies even if present at moderate titers reduce uptake of the Adenoviral vectors by cells, including antigen presenting cells [57] .
Conclusion and Recommendations
Advances in molecular virology in concert with viral immunology now allow for the genetic engineering of vectors expressing solely those viral antigens that induce immune correlates of protection. Adenoviruses have moved to the forefront of vaccinology and are showing substantial promise as vehicles for antigen delivery for a number of vaccines currently being developed. Due to the versatility and variety of Adenovirus serotypes, they will be valuable tools for developing vaccines against new pathogens and against those to which vaccines have yet to be discovered. Most vectors currently used as vaccine carriers are deleted in E1. This renders the vectors replication defective, to increase the permitted size of the insert and also allows for sustained antigen presentation by reducing the vectors' ability to induce death of the infected cells. The potential for Adenoviruses to elicit powerful B cell and T cell responses in the mammalian host are the main reason for the use of these vectors in vaccine development. Preexisting Adenoviral vector immunity has been shown to decrease the immunogenicity of Adenoviral based vaccines in animal models. Several strategies to overcome this limitation are being explored and have shown promise in pre-clinical studies. One such strategy involves the use of vectors derived from human Adenoviruses specially HAd 5. Based on the above conclusion the following recommendations are forwarded:
 Adenoviral vaccine vectors must be thoroughly evaluated for potentially harmful immunological reactions on the host immune system.  Extensive research on Adeno viral vaccine vectors should be undertaken for effective utilization and commercialization of veterinary use. 
